ES2734743T3 - Métodos y composiciones para la inhibición específica de beta-catenina por RNA bicatenario - Google Patents

Info

Publication number

ES2734743T3

ES2734743T3 ES16155285T ES16155285T ES2734743T3 ES 2734743 T3 ES2734743 T3 ES 2734743T3 ES 16155285 T ES16155285 T ES 16155285T ES 16155285 T ES16155285 T ES 16155285T ES 2734743 T3 ES2734743 T3 ES 2734743T3

Authority

ES

Spain

Prior art keywords

chain

seq

rna

catenin

dsrna

Prior art date

2010-07-06

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• Discuss

• 108091032973 (ribonucleotides)n+m Proteins 0.000 title claims description 709
• 238000000034 method Methods 0.000 title claims description 105
• 239000000203 mixture Substances 0.000 title claims description 81
• 102000040650 (ribonucleotides)n+m Human genes 0.000 title claims description 45
• 230000005764 inhibitory process Effects 0.000 title claims description 40
• 102000015735 Beta-catenin Human genes 0.000 title abstract description 6
• 108060000903 Beta-catenin Proteins 0.000 title abstract description 6
• 125000003729 nucleotide group Chemical group 0.000 claims abstract description 414
• 239000002773 nucleotide Substances 0.000 claims abstract description 343
• 150000007523 nucleic acids Chemical group 0.000 claims abstract description 189
• 108090000623 proteins and genes Proteins 0.000 claims abstract description 122
• 230000000295 complement effect Effects 0.000 claims abstract description 99
• 230000014509 gene expression Effects 0.000 claims abstract description 98
• 210000004962 mammalian cell Anatomy 0.000 claims abstract description 48
• 229920002477 rna polymer Polymers 0.000 claims abstract description 18
• 210000004027 cell Anatomy 0.000 claims description 258
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 112
• 238000012986 modification Methods 0.000 claims description 95
• 230000004048 modification Effects 0.000 claims description 94
• 201000010099 disease Diseases 0.000 claims description 68
• 230000009467 reduction Effects 0.000 claims description 66
• 206010028980 Neoplasm Diseases 0.000 claims description 49
• 208000035475 disorder Diseases 0.000 claims description 44
• 201000011510 cancer Diseases 0.000 claims description 40
• 238000000338 in vitro Methods 0.000 claims description 38
• 239000003814 drug Substances 0.000 claims description 32
• -1 infusion Substances 0.000 claims description 28
• 241000124008 Mammalia Species 0.000 claims description 17
• 235000000346 sugar Nutrition 0.000 claims description 17
• 239000008194 pharmaceutical composition Substances 0.000 claims description 15
• 230000012010 growth Effects 0.000 claims description 14
• 230000002829 reductive effect Effects 0.000 claims description 14
• 229940079593 drug Drugs 0.000 claims description 12
• 239000003937 drug carrier Substances 0.000 claims description 10
• 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 8
• 210000004881 tumor cell Anatomy 0.000 claims description 7
• 238000004519 manufacturing process Methods 0.000 claims description 6
• 239000002253 acid Substances 0.000 claims description 5
• 239000000443 aerosol Substances 0.000 claims description 5
• 208000014018 liver neoplasm Diseases 0.000 claims description 5
• 238000001802 infusion Methods 0.000 claims description 4
• 239000007927 intramuscular injection Substances 0.000 claims description 4
• 239000007928 intraperitoneal injection Substances 0.000 claims description 4
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 4
• UFEJKYYYVXYMMS-UHFFFAOYSA-N methylcarbamic acid Chemical compound CNC(O)=O UFEJKYYYVXYMMS-UHFFFAOYSA-N 0.000 claims description 4
• 230000000699 topical effect Effects 0.000 claims description 4
• 238000010255 intramuscular injection Methods 0.000 claims description 3
• 238000010253 intravenous injection Methods 0.000 claims description 3
• 230000002378 acidificating effect Effects 0.000 claims description 2
• 125000001153 fluoro group Chemical group F* 0.000 claims 1
• 238000010254 subcutaneous injection Methods 0.000 claims 1
• 239000007929 subcutaneous injection Substances 0.000 claims 1
• 102000039446 nucleic acids Human genes 0.000 abstract description 132
• 108020004707 nucleic acids Proteins 0.000 abstract description 132
• 230000000692 anti-sense effect Effects 0.000 description 370
• 239000003795 chemical substances by application Substances 0.000 description 277
• 239000000178 monomer Substances 0.000 description 221
• 102000053602 DNA Human genes 0.000 description 126
• 108020004414 DNA Proteins 0.000 description 126
• 108010067316 Catenins Proteins 0.000 description 111
• 102000016362 Catenins Human genes 0.000 description 105
• 108091034117 Oligonucleotide Proteins 0.000 description 99
• 230000002401 inhibitory effect Effects 0.000 description 79
• 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 76
• 102100023387 Endoribonuclease Dicer Human genes 0.000 description 75
• 241000282414 Homo sapiens Species 0.000 description 72
• 108091028043 Nucleic acid sequence Proteins 0.000 description 68
• 238000003776 cleavage reaction Methods 0.000 description 54
• 230000000694 effects Effects 0.000 description 54
• 230000007017 scission Effects 0.000 description 54
• 102000004169 proteins and genes Human genes 0.000 description 41
• 108020004999 messenger RNA Proteins 0.000 description 39
• JTTIOYHBNXDJOD-UHFFFAOYSA-N 2,4,6-triaminopyrimidine Chemical compound NC1=CC(N)=NC(N)=N1 JTTIOYHBNXDJOD-UHFFFAOYSA-N 0.000 description 36
• 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 description 36
• 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 description 36
• 150000001875 compounds Chemical class 0.000 description 35
• 239000002299 complementary DNA Substances 0.000 description 34
• 238000001890 transfection Methods 0.000 description 33
• 238000011282 treatment Methods 0.000 description 33
• 241000699666 Mus <mouse, genus> Species 0.000 description 31
• 108091028664 Ribonucleotide Proteins 0.000 description 31
• 230000009368 gene silencing by RNA Effects 0.000 description 31
• 239000002336 ribonucleotide Substances 0.000 description 31
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 29
• 230000008685 targeting Effects 0.000 description 29
• 125000002637 deoxyribonucleotide group Chemical group 0.000 description 28
• 108010039224 Amidophosphoribosyltransferase Proteins 0.000 description 27
• 239000005547 deoxyribonucleotide Substances 0.000 description 25
• 238000009396 hybridization Methods 0.000 description 25
• 239000003607 modifier Substances 0.000 description 25
• 230000003389 potentiating effect Effects 0.000 description 25
• 238000001727 in vivo Methods 0.000 description 24
• 238000009472 formulation Methods 0.000 description 22
• 238000012545 processing Methods 0.000 description 22
• 125000002652 ribonucleotide group Chemical group 0.000 description 22
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 21
• 238000003556 assay Methods 0.000 description 20
• 239000003112 inhibitor Substances 0.000 description 20
• 210000001519 tissue Anatomy 0.000 description 20
• 230000036515 potency Effects 0.000 description 18
• 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 17
• 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 17
• 238000010171 animal model Methods 0.000 description 16
• 230000015556 catabolic process Effects 0.000 description 16
• 238000004113 cell culture Methods 0.000 description 16
• 238000006731 degradation reaction Methods 0.000 description 16
• 239000000872 buffer Substances 0.000 description 15
• 239000001257 hydrogen Substances 0.000 description 15
• 229910052739 hydrogen Inorganic materials 0.000 description 15
• 239000000758 substrate Substances 0.000 description 15
• HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 15
• 238000011156 evaluation Methods 0.000 description 14
• 239000000463 material Substances 0.000 description 14
• 230000008569 process Effects 0.000 description 14
• 101710163270 Nuclease Proteins 0.000 description 13
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
• 230000006378 damage Effects 0.000 description 13
• 239000012071 phase Substances 0.000 description 13
• 108090000765 processed proteins & peptides Proteins 0.000 description 13
• 238000012360 testing method Methods 0.000 description 13
• 101000651036 Arabidopsis thaliana Galactolipid galactosyltransferase SFR2, chloroplastic Proteins 0.000 description 12
• 102100028914 Catenin beta-1 Human genes 0.000 description 12
• 206010009944 Colon cancer Diseases 0.000 description 12
• 101150084233 ago2 gene Proteins 0.000 description 12
• 238000013461 design Methods 0.000 description 12
• 239000000523 sample Substances 0.000 description 12
• 239000000243 solution Substances 0.000 description 12
• 238000006243 chemical reaction Methods 0.000 description 11
• 239000000126 substance Substances 0.000 description 11
• 238000006467 substitution reaction Methods 0.000 description 11
• 230000001225 therapeutic effect Effects 0.000 description 11
• 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 description 10
• 230000027455 binding Effects 0.000 description 10
• 230000015572 biosynthetic process Effects 0.000 description 10
• 210000000805 cytoplasm Anatomy 0.000 description 10
• 125000005647 linker group Chemical group 0.000 description 10
• CJWXCNXHAIFFMH-AVZHFPDBSA-N n-[(2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5r)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxy-3,5-dihydroxy-6-methyloxan-4-yl]acetamide Chemical compound C[C@H]1O[C@@H](O[C@@H]([C@@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)[C@H](O)[C@@H](NC(C)=O)[C@@H]1O CJWXCNXHAIFFMH-AVZHFPDBSA-N 0.000 description 10
• 229920001184 polypeptide Polymers 0.000 description 10
• 102000004196 processed proteins & peptides Human genes 0.000 description 10
• 230000002062 proliferating effect Effects 0.000 description 10
• 229940124597 therapeutic agent Drugs 0.000 description 10
• 102100040004 Gamma-glutamylcyclotransferase Human genes 0.000 description 9
• 241000282412 Homo Species 0.000 description 9
• 101000886680 Homo sapiens Gamma-glutamylcyclotransferase Proteins 0.000 description 9
• 229910019142 PO4 Inorganic materials 0.000 description 9
• 108020004459 Small interfering RNA Proteins 0.000 description 9
• 238000011161 development Methods 0.000 description 9
• 230000018109 developmental process Effects 0.000 description 9
• 230000006870 function Effects 0.000 description 9
• 150000002632 lipids Chemical class 0.000 description 9
• 239000010452 phosphate Substances 0.000 description 9
• 238000002360 preparation method Methods 0.000 description 9
• 239000000047 product Substances 0.000 description 9
• 239000011734 sodium Substances 0.000 description 9
• 241000894007 species Species 0.000 description 9
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 9
• 239000013598 vector Substances 0.000 description 9
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 8
• 102100024375 Gamma-glutamylaminecyclotransferase Human genes 0.000 description 8
• 101710201613 Gamma-glutamylaminecyclotransferase Proteins 0.000 description 8
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
• 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 8
• 241000699670 Mus sp. Species 0.000 description 8
• 239000003153 chemical reaction reagent Substances 0.000 description 8
• 238000010348 incorporation Methods 0.000 description 8
• 239000007924 injection Substances 0.000 description 8
• 238000002347 injection Methods 0.000 description 8
• 230000001404 mediated effect Effects 0.000 description 8
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 8
• 235000021317 phosphate Nutrition 0.000 description 8
• 238000011144 upstream manufacturing Methods 0.000 description 8
• 239000003981 vehicle Substances 0.000 description 8
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 7
• 108091093088 Amplicon Proteins 0.000 description 7
• 101001128634 Homo sapiens NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial Proteins 0.000 description 7
• 241001465754 Metazoa Species 0.000 description 7
• 102100032194 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 2, mitochondrial Human genes 0.000 description 7
• 238000011529 RT qPCR Methods 0.000 description 7
• 230000009471 action Effects 0.000 description 7
• 125000002091 cationic group Chemical group 0.000 description 7
• 230000010261 cell growth Effects 0.000 description 7
• 239000000284 extract Substances 0.000 description 7
• 230000003993 interaction Effects 0.000 description 7
• 238000001990 intravenous administration Methods 0.000 description 7
• 238000005259 measurement Methods 0.000 description 7
• 238000010369 molecular cloning Methods 0.000 description 7
• 102000040430 polynucleotide Human genes 0.000 description 7
• 108091033319 polynucleotide Proteins 0.000 description 7
• 239000002157 polynucleotide Substances 0.000 description 7
• 210000002966 serum Anatomy 0.000 description 7
• 238000010561 standard procedure Methods 0.000 description 7
• 238000013456 study Methods 0.000 description 7
• 208000024891 symptom Diseases 0.000 description 7
• 231100000419 toxicity Toxicity 0.000 description 7
• 230000001988 toxicity Effects 0.000 description 7
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
• 102000000905 Cadherin Human genes 0.000 description 6
• 108050007957 Cadherin Proteins 0.000 description 6
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
• 101000700734 Homo sapiens Serine/arginine-rich splicing factor 9 Proteins 0.000 description 6
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 6
• 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 6
• 102000005891 Pancreatic ribonuclease Human genes 0.000 description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 108010057163 Ribonuclease III Proteins 0.000 description 6
• 102000003661 Ribonuclease III Human genes 0.000 description 6
• 102100029288 Serine/arginine-rich splicing factor 9 Human genes 0.000 description 6
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
• 102000013814 Wnt Human genes 0.000 description 6
• 108050003627 Wnt Proteins 0.000 description 6
• 238000010521 absorption reaction Methods 0.000 description 6
• 238000007792 addition Methods 0.000 description 6
• 230000001413 cellular effect Effects 0.000 description 6
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
• 238000001514 detection method Methods 0.000 description 6
• 238000002474 experimental method Methods 0.000 description 6
• 239000012091 fetal bovine serum Substances 0.000 description 6
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
• 238000000099 in vitro assay Methods 0.000 description 6
• 230000000670 limiting effect Effects 0.000 description 6
• 239000002502 liposome Substances 0.000 description 6
• 210000004185 liver Anatomy 0.000 description 6
• 238000002844 melting Methods 0.000 description 6
• 230000008018 melting Effects 0.000 description 6
• 230000037361 pathway Effects 0.000 description 6
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 6
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
• 230000004044 response Effects 0.000 description 6
• 239000011780 sodium chloride Substances 0.000 description 6
• 238000013518 transcription Methods 0.000 description 6
• 230000035897 transcription Effects 0.000 description 6
• 230000004614 tumor growth Effects 0.000 description 6
• 229940035893 uracil Drugs 0.000 description 6
• 102100039819 Actin, alpha cardiac muscle 1 Human genes 0.000 description 5
• 102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 description 5
• 101710102163 Atrial natriuretic peptide receptor 1 Proteins 0.000 description 5
• BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 5
• 101000959247 Homo sapiens Actin, alpha cardiac muscle 1 Proteins 0.000 description 5
• 108700020796 Oncogene Proteins 0.000 description 5
• OIFWQOKDSPDILA-XLPZGREQSA-N [(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl dihydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](N=[N+]=[N-])C1 OIFWQOKDSPDILA-XLPZGREQSA-N 0.000 description 5
• 230000008859 change Effects 0.000 description 5
• OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 5
• OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 5
• 238000005516 engineering process Methods 0.000 description 5
• 239000000499 gel Substances 0.000 description 5
• 230000002068 genetic effect Effects 0.000 description 5
• 230000001965 increasing effect Effects 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 239000002609 medium Substances 0.000 description 5
• 238000011002 quantification Methods 0.000 description 5
• 238000011160 research Methods 0.000 description 5
• 238000007920 subcutaneous administration Methods 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 238000013519 translation Methods 0.000 description 5
• 230000005740 tumor formation Effects 0.000 description 5
• LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 4
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
• 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 102100035683 Axin-2 Human genes 0.000 description 4
• 101150037241 CTNNB1 gene Proteins 0.000 description 4
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
• 102000004190 Enzymes Human genes 0.000 description 4
• 108090000790 Enzymes Proteins 0.000 description 4
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
• 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 4
• 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 4
• 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 4
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
• 108091093037 Peptide nucleic acid Proteins 0.000 description 4
• 102100038603 Probable ubiquitin carboxyl-terminal hydrolase FAF-X Human genes 0.000 description 4
• 125000003275 alpha amino acid group Chemical group 0.000 description 4
• 238000004458 analytical method Methods 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 239000011230 binding agent Substances 0.000 description 4
• 230000037396 body weight Effects 0.000 description 4
• 238000005520 cutting process Methods 0.000 description 4
• 230000003831 deregulation Effects 0.000 description 4
• 238000004128 high performance liquid chromatography Methods 0.000 description 4
• 210000005260 human cell Anatomy 0.000 description 4
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
• 230000028993 immune response Effects 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 239000000314 lubricant Substances 0.000 description 4
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
• 238000012423 maintenance Methods 0.000 description 4
• 230000036210 malignancy Effects 0.000 description 4
• 239000011159 matrix material Substances 0.000 description 4
• 201000001441 melanoma Diseases 0.000 description 4
• 230000035772 mutation Effects 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 230000000069 prophylactic effect Effects 0.000 description 4
• 230000011664 signaling Effects 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 210000000130 stem cell Anatomy 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
• 230000003612 virological effect Effects 0.000 description 4
• 238000005406 washing Methods 0.000 description 4
• 239000002699 waste material Substances 0.000 description 4
• 238000001262 western blot Methods 0.000 description 4
• VUFNLQXQSDUXKB-DOFZRALJSA-N 2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]ethyl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCCOC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 VUFNLQXQSDUXKB-DOFZRALJSA-N 0.000 description 3
• OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 3
• KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 3
• OZFPSOBLQZPIAV-UHFFFAOYSA-N 5-nitro-1h-indole Chemical compound [O-][N+](=O)C1=CC=C2NC=CC2=C1 OZFPSOBLQZPIAV-UHFFFAOYSA-N 0.000 description 3
• 108010085238 Actins Proteins 0.000 description 3
• 102000007469 Actins Human genes 0.000 description 3
• 229930024421 Adenine Natural products 0.000 description 3
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical group NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
• 108700028369 Alleles Proteins 0.000 description 3
• 101700047552 Axin-2 Proteins 0.000 description 3
• 102100028003 Catenin alpha-1 Human genes 0.000 description 3
• 206010008342 Cervix carcinoma Diseases 0.000 description 3
• 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 3
• 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 3
• 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 3
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
• 102000001267 GSK3 Human genes 0.000 description 3
• 108060006662 GSK3 Proteins 0.000 description 3
• 108010010803 Gelatin Proteins 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• 102100034343 Integrase Human genes 0.000 description 3
• 208000000172 Medulloblastoma Diseases 0.000 description 3
• 108700011259 MicroRNAs Proteins 0.000 description 3
• 238000000636 Northern blotting Methods 0.000 description 3
• 206010033128 Ovarian cancer Diseases 0.000 description 3
• 206010061535 Ovarian neoplasm Diseases 0.000 description 3
• 108091000080 Phosphotransferase Proteins 0.000 description 3
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
• 108091027568 Single-stranded nucleotide Proteins 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
• 229960000643 adenine Drugs 0.000 description 3
• 230000003321 amplification Effects 0.000 description 3
• 239000003242 anti bacterial agent Substances 0.000 description 3
• 230000033228 biological regulation Effects 0.000 description 3
• 210000000481 breast Anatomy 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 201000010881 cervical cancer Diseases 0.000 description 3
• 238000007385 chemical modification Methods 0.000 description 3
• 238000010367 cloning Methods 0.000 description 3
• 208000029742 colonic neoplasm Diseases 0.000 description 3
• 229940104302 cytosine Drugs 0.000 description 3
• 230000001086 cytosolic effect Effects 0.000 description 3
• 238000012217 deletion Methods 0.000 description 3
• 230000037430 deletion Effects 0.000 description 3
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
• 239000006185 dispersion Substances 0.000 description 3
• 239000002612 dispersion medium Substances 0.000 description 3
• 239000000975 dye Substances 0.000 description 3
• 239000008273 gelatin Substances 0.000 description 3
• 229920000159 gelatin Polymers 0.000 description 3
• 235000019322 gelatine Nutrition 0.000 description 3
• 235000011852 gelatine desserts Nutrition 0.000 description 3
• 235000011187 glycerol Nutrition 0.000 description 3
• 208000014829 head and neck neoplasm Diseases 0.000 description 3
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
• 239000003701 inert diluent Substances 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• 210000005228 liver tissue Anatomy 0.000 description 3
• 201000005202 lung cancer Diseases 0.000 description 3
• 208000020816 lung neoplasm Diseases 0.000 description 3
• 239000006166 lysate Substances 0.000 description 3
• 239000012139 lysis buffer Substances 0.000 description 3
• 238000007069 methylation reaction Methods 0.000 description 3
• 239000002679 microRNA Substances 0.000 description 3
• 150000004712 monophosphates Chemical class 0.000 description 3
• NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 3
• 239000002105 nanoparticle Substances 0.000 description 3
• 238000003199 nucleic acid amplification method Methods 0.000 description 3
• 239000002777 nucleoside Substances 0.000 description 3
• 150000003833 nucleoside derivatives Chemical class 0.000 description 3
• 210000004940 nucleus Anatomy 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• 230000002974 pharmacogenomic effect Effects 0.000 description 3
• 239000002953 phosphate buffered saline Substances 0.000 description 3
• 230000026731 phosphorylation Effects 0.000 description 3
• 238000006366 phosphorylation reaction Methods 0.000 description 3
• 102000020233 phosphotransferase Human genes 0.000 description 3
• 239000006187 pill Substances 0.000 description 3
• 208000001095 pilomatrixoma Diseases 0.000 description 3
• 210000002381 plasma Anatomy 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 229920000642 polymer Polymers 0.000 description 3
• 235000011056 potassium acetate Nutrition 0.000 description 3
• 230000003449 preventive effect Effects 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 3
• 238000003753 real-time PCR Methods 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 230000001177 retroviral effect Effects 0.000 description 3
• 229910001415 sodium ion Inorganic materials 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 231100000331 toxic Toxicity 0.000 description 3
• 230000002588 toxic effect Effects 0.000 description 3
• 230000009261 transgenic effect Effects 0.000 description 3
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
• LOJNBPNACKZWAI-UHFFFAOYSA-N 3-nitro-1h-pyrrole Chemical compound [O-][N+](=O)C=1C=CNC=1 LOJNBPNACKZWAI-UHFFFAOYSA-N 0.000 description 2
• LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• 108010014223 Armadillo Domain Proteins Proteins 0.000 description 2
• 108700012045 Axin Proteins 0.000 description 2
• 208000003174 Brain Neoplasms Diseases 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• 101710106619 Catenin alpha-3 Proteins 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• 108010066133 D-octopine dehydrogenase Proteins 0.000 description 2
• 108010041986 DNA Vaccines Proteins 0.000 description 2
• 229940021995 DNA vaccine Drugs 0.000 description 2
• 241000252212 Danio rerio Species 0.000 description 2
• 241000289632 Dasypodidae Species 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 241000196324 Embryophyta Species 0.000 description 2
• 108010042407 Endonucleases Proteins 0.000 description 2
• 102000002494 Endoribonucleases Human genes 0.000 description 2
• 108010093099 Endoribonucleases Proteins 0.000 description 2
• 108060002716 Exonuclease Proteins 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 2
• 102100022662 Guanylyl cyclase C Human genes 0.000 description 2
• 101710198293 Guanylyl cyclase C Proteins 0.000 description 2
• 101000896557 Homo sapiens Eukaryotic translation initiation factor 3 subunit B Proteins 0.000 description 2
• 101000893303 Homo sapiens Glycine amidinotransferase, mitochondrial Proteins 0.000 description 2
• 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 2
• 101001024703 Homo sapiens Nck-associated protein 5 Proteins 0.000 description 2
• 101000869690 Homo sapiens Protein S100-A8 Proteins 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
• 101710203526 Integrase Proteins 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• 241000699660 Mus musculus Species 0.000 description 2
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
• DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
• 102100036946 Nck-associated protein 5 Human genes 0.000 description 2
• 108091092724 Noncoding DNA Proteins 0.000 description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
• 108010029485 Protein Isoforms Proteins 0.000 description 2
• 102000001708 Protein Isoforms Human genes 0.000 description 2
• 102100032442 Protein S100-A8 Human genes 0.000 description 2
• 102100034207 Protein argonaute-2 Human genes 0.000 description 2
• 230000007022 RNA scission Effects 0.000 description 2
• 102000006382 Ribonucleases Human genes 0.000 description 2
• 108010083644 Ribonucleases Proteins 0.000 description 2
• 241000283984 Rodentia Species 0.000 description 2
• 206010039491 Sarcoma Diseases 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• 108091027967 Small hairpin RNA Proteins 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 201000008754 Tenosynovial giant cell tumor Diseases 0.000 description 2
• 102000040945 Transcription factor Human genes 0.000 description 2
• 108091023040 Transcription factor Proteins 0.000 description 2
• 108700019146 Transgenes Proteins 0.000 description 2
• 230000004156 Wnt signaling pathway Effects 0.000 description 2
• 238000002835 absorbance Methods 0.000 description 2
• 230000004913 activation Effects 0.000 description 2
• 239000000783 alginic acid Substances 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 229960001126 alginic acid Drugs 0.000 description 2
• 150000004781 alginic acids Chemical class 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 150000001413 amino acids Chemical group 0.000 description 2
• 210000004102 animal cell Anatomy 0.000 description 2
• 230000000844 anti-bacterial effect Effects 0.000 description 2
• 230000003466 anti-cipated effect Effects 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 235000019606 astringent taste Nutrition 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 230000036952 cancer formation Effects 0.000 description 2
• 230000005907 cancer growth Effects 0.000 description 2
• 210000000234 capsid Anatomy 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 229910002092 carbon dioxide Inorganic materials 0.000 description 2
• 229910002091 carbon monoxide Inorganic materials 0.000 description 2
• 150000001768 cations Chemical class 0.000 description 2
• 238000013043 cell viability test Methods 0.000 description 2
• 230000033077 cellular process Effects 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 108091036078 conserved sequence Proteins 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 239000008120 corn starch Substances 0.000 description 2
• 238000002716 delivery method Methods 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• 238000010586 diagram Methods 0.000 description 2
• 208000035647 diffuse type tenosynovial giant cell tumor Diseases 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 239000012636 effector Substances 0.000 description 2
• 238000001962 electrophoresis Methods 0.000 description 2
• 102000013165 exonuclease Human genes 0.000 description 2
• 238000010195 expression analysis Methods 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 235000013355 food flavoring agent Nutrition 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 125000000623 heterocyclic group Chemical group 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 210000005007 innate immune system Anatomy 0.000 description 2
• 230000010468 interferon response Effects 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000004255 ion exchange chromatography Methods 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 2
• 239000011654 magnesium acetate Substances 0.000 description 2
• 235000011285 magnesium acetate Nutrition 0.000 description 2
• 229940069446 magnesium acetate Drugs 0.000 description 2
• 235000019359 magnesium stearate Nutrition 0.000 description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
• 210000001161 mammalian embryo Anatomy 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 230000009401 metastasis Effects 0.000 description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 239000003094 microcapsule Substances 0.000 description 2
• 239000011859 microparticle Substances 0.000 description 2
• 238000012544 monitoring process Methods 0.000 description 2
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
• 239000002088 nanocapsule Substances 0.000 description 2
• 108091027963 non-coding RNA Proteins 0.000 description 2
• 231100000956 nontoxicity Toxicity 0.000 description 2
• 108010058731 nopaline synthase Proteins 0.000 description 2
• 238000010606 normalization Methods 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 230000002611 ovarian Effects 0.000 description 2
• 201000002528 pancreatic cancer Diseases 0.000 description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• HMFHBZSHGGEWLO-UHFFFAOYSA-N pentofuranose Chemical group OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
• UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
• 239000013612 plasmid Substances 0.000 description 2
• GUUBJKMBDULZTE-UHFFFAOYSA-M potassium;2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid;hydroxide Chemical compound [OH-].[K+].OCCN1CCN(CCS(O)(=O)=O)CC1 GUUBJKMBDULZTE-UHFFFAOYSA-M 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• 210000002307 prostate Anatomy 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• ZSKGQVFRTSEPJT-UHFFFAOYSA-N pyrrole-2-carboxaldehyde Chemical compound O=CC1=CC=CN1 ZSKGQVFRTSEPJT-UHFFFAOYSA-N 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• 230000008929 regeneration Effects 0.000 description 2
• 238000011069 regeneration method Methods 0.000 description 2
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
• 238000003757 reverse transcription PCR Methods 0.000 description 2
• 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
• 239000004055 small Interfering RNA Substances 0.000 description 2
• 239000007790 solid phase Substances 0.000 description 2
• 230000000392 somatic effect Effects 0.000 description 2
• 108010068698 spleen exonuclease Proteins 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 230000000638 stimulation Effects 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 239000006228 supernatant Substances 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 208000002918 testicular germ cell tumor Diseases 0.000 description 2
• 231100001274 therapeutic index Toxicity 0.000 description 2
• 229940113082 thymine Drugs 0.000 description 2
• 239000012096 transfection reagent Substances 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical class C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 description 1
• LKUDPHPHKOZXCD-UHFFFAOYSA-N 1,3,5-trimethoxybenzene Chemical compound COC1=CC(OC)=CC(OC)=C1 LKUDPHPHKOZXCD-UHFFFAOYSA-N 0.000 description 1
• SGKGZYGMLGVQHP-ZOQUXTDFSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-methylpyrimidine-2,4-dione Chemical compound CC1=CC(=O)NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SGKGZYGMLGVQHP-ZOQUXTDFSA-N 0.000 description 1
• OAXSBZVGKPGEDJ-UHFFFAOYSA-N 1-methyl-4h-pyrazolo[4,3-d]pyrimidine-5,7-dione Chemical compound N1C(=O)NC(=O)C2=C1C=NN2C OAXSBZVGKPGEDJ-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• KHWCHTKSEGGWEX-RRKCRQDMSA-N 2'-deoxyadenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 KHWCHTKSEGGWEX-RRKCRQDMSA-N 0.000 description 1
• LTFMZDNNPPEQNG-KVQBGUIXSA-N 2'-deoxyguanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](COP(O)(O)=O)O1 LTFMZDNNPPEQNG-KVQBGUIXSA-N 0.000 description 1
• IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
• XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 1
• AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
• MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
• GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical class OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
• 108020005345 3' Untranslated Regions Proteins 0.000 description 1
• 102100030786 3'-5' exoribonuclease 1 Human genes 0.000 description 1
• VPLZGVOSFFCKFC-UHFFFAOYSA-N 3-methyluracil Chemical compound CN1C(=O)C=CNC1=O VPLZGVOSFFCKFC-UHFFFAOYSA-N 0.000 description 1
• PHAFOFIVSNSAPQ-UHFFFAOYSA-N 4-fluoro-6-methyl-1h-benzimidazole Chemical compound CC1=CC(F)=C2NC=NC2=C1 PHAFOFIVSNSAPQ-UHFFFAOYSA-N 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 1
• QCXGJTGMGJOYDP-UHFFFAOYSA-N 4-methyl-1h-benzimidazole Chemical compound CC1=CC=CC2=C1N=CN2 QCXGJTGMGJOYDP-UHFFFAOYSA-N 0.000 description 1
• 108020003589 5' Untranslated Regions Proteins 0.000 description 1
• 102100036962 5'-3' exoribonuclease 1 Human genes 0.000 description 1
• 102100039222 5'-3' exoribonuclease 2 Human genes 0.000 description 1
• ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
• AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
• ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
• WSGURAYTCUVDQL-UHFFFAOYSA-N 5-nitro-1h-indazole Chemical compound [O-][N+](=O)C1=CC=C2NN=CC2=C1 WSGURAYTCUVDQL-UHFFFAOYSA-N 0.000 description 1
• QCHLWIPINNRBSG-UHFFFAOYSA-N 6-thiophen-2-yl-7h-purin-2-amine Chemical compound C=12NC=NC2=NC(N)=NC=1C1=CC=CS1 QCHLWIPINNRBSG-UHFFFAOYSA-N 0.000 description 1
• 102100021308 60S ribosomal protein L23 Human genes 0.000 description 1
• WIPHNVWGXOHNEF-UHFFFAOYSA-N 7-thiophen-2-yl-1h-imidazo[4,5-b]pyridine Chemical compound C1=CSC(C=2C=3N=CNC=3N=CC=2)=C1 WIPHNVWGXOHNEF-UHFFFAOYSA-N 0.000 description 1
• BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical compound C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 101150096411 AXIN2 gene Proteins 0.000 description 1
• 208000035657 Abasia Diseases 0.000 description 1
• 206010000125 Abnormal dreams Diseases 0.000 description 1
• 108010000700 Acetolactate synthase Proteins 0.000 description 1
• 208000001783 Adamantinoma Diseases 0.000 description 1
• 208000003200 Adenoma Diseases 0.000 description 1
• 206010001233 Adenoma benign Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 208000005748 Aggressive Fibromatosis Diseases 0.000 description 1
• 102000003730 Alpha-catenin Human genes 0.000 description 1
• 108090000020 Alpha-catenin Proteins 0.000 description 1
• 102100032187 Androgen receptor Human genes 0.000 description 1
• 108020004491 Antisense DNA Proteins 0.000 description 1
• 108020005544 Antisense RNA Proteins 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 102100035682 Axin-1 Human genes 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 108091028026 C-DNA Proteins 0.000 description 1
• 102100025805 Cadherin-1 Human genes 0.000 description 1
• 102100024153 Cadherin-15 Human genes 0.000 description 1
• 102100036364 Cadherin-2 Human genes 0.000 description 1
• 101100172628 Caenorhabditis elegans eri-1 gene Proteins 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
• 102000053642 Catalytic RNA Human genes 0.000 description 1
• 102100028906 Catenin delta-1 Human genes 0.000 description 1
• 108091007854 Cdh1/Fizzy-related Proteins 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 201000009047 Chordoma Diseases 0.000 description 1
• UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 206010055665 Corneal neovascularisation Diseases 0.000 description 1
• 102000004420 Creatine Kinase Human genes 0.000 description 1
• 108010042126 Creatine kinase Proteins 0.000 description 1
• 108010058546 Cyclin D1 Proteins 0.000 description 1
• 102100026865 Cyclin-dependent kinase 5 activator 1 Human genes 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• 238000001712 DNA sequencing Methods 0.000 description 1
• 206010059352 Desmoid tumour Diseases 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• 241000255925 Diptera Species 0.000 description 1
• 108050007016 Dishevelled Proteins 0.000 description 1
• 102000017944 Dishevelled Human genes 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• 108700029572 Drosophila ARM Proteins 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 101150110503 END3 gene Proteins 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 102100031780 Endonuclease Human genes 0.000 description 1
• 102000004533 Endonucleases Human genes 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 101150016266 Eri1 gene Proteins 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• 239000005977 Ethylene Substances 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 102100037091 Exonuclease V Human genes 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• 102100038644 Four and a half LIM domains protein 2 Human genes 0.000 description 1
• 101710181403 Frizzled Proteins 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
• 102000002464 Galactosidases Human genes 0.000 description 1
• 108010093031 Galactosidases Proteins 0.000 description 1
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
• 208000007569 Giant Cell Tumors Diseases 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
• 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 206010019043 Hair follicle tumour benign Diseases 0.000 description 1
• 206010073069 Hepatic cancer Diseases 0.000 description 1
• 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
• 102100022054 Hepatocyte nuclear factor 4-alpha Human genes 0.000 description 1
• 206010019842 Hepatomegaly Diseases 0.000 description 1
• 102100022846 Histone acetyltransferase KAT2B Human genes 0.000 description 1
• 108010033040 Histones Proteins 0.000 description 1
• 241001272567 Hominoidea Species 0.000 description 1
• 101000938755 Homo sapiens 3'-5' exoribonuclease 1 Proteins 0.000 description 1
• 101000804879 Homo sapiens 5'-3' exoribonuclease 1 Proteins 0.000 description 1
• 101000745788 Homo sapiens 5'-3' exoribonuclease 2 Proteins 0.000 description 1
• 101000675833 Homo sapiens 60S ribosomal protein L23 Proteins 0.000 description 1
• 101000874566 Homo sapiens Axin-1 Proteins 0.000 description 1
• 101000762242 Homo sapiens Cadherin-15 Proteins 0.000 description 1
• 101000714537 Homo sapiens Cadherin-2 Proteins 0.000 description 1
• 101000714553 Homo sapiens Cadherin-3 Proteins 0.000 description 1
• 101000859063 Homo sapiens Catenin alpha-1 Proteins 0.000 description 1
• 101000916264 Homo sapiens Catenin delta-1 Proteins 0.000 description 1
• 101000749829 Homo sapiens Connector enhancer of kinase suppressor of ras 3 Proteins 0.000 description 1
• 101000881977 Homo sapiens Exonuclease V Proteins 0.000 description 1
• 101001031714 Homo sapiens Four and a half LIM domains protein 2 Proteins 0.000 description 1
• 101001045740 Homo sapiens Hepatocyte nuclear factor 4-alpha Proteins 0.000 description 1
• 101001047006 Homo sapiens Histone acetyltransferase KAT2B Proteins 0.000 description 1
• 101001043764 Homo sapiens Inhibitor of nuclear factor kappa-B kinase subunit alpha Proteins 0.000 description 1
• 101000972291 Homo sapiens Lymphoid enhancer-binding factor 1 Proteins 0.000 description 1
• 101001057193 Homo sapiens Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Proteins 0.000 description 1
• 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
• 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
• 101001125327 Homo sapiens Na(+)/H(+) exchange regulatory cofactor NHE-RF1 Proteins 0.000 description 1
• 101000617536 Homo sapiens Presenilin-1 Proteins 0.000 description 1
• 101000808592 Homo sapiens Probable ubiquitin carboxyl-terminal hydrolase FAF-X Proteins 0.000 description 1
• 101000994471 Homo sapiens Protein Jade-1 Proteins 0.000 description 1
• 101000780643 Homo sapiens Protein argonaute-2 Proteins 0.000 description 1
• 101000910825 Homo sapiens Protein chibby homolog 1 Proteins 0.000 description 1
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• 101000606545 Homo sapiens Receptor-type tyrosine-protein phosphatase F Proteins 0.000 description 1
• 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 description 1
• 101001087426 Homo sapiens Tyrosine-protein phosphatase non-receptor type 14 Proteins 0.000 description 1
• 101000608672 Homo sapiens Uveal autoantigen with coiled-coil domains and ankyrin repeats Proteins 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 102100021892 Inhibitor of nuclear factor kappa-B kinase subunit alpha Human genes 0.000 description 1
• 102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 description 1
• 101710205525 Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• 239000005089 Luciferase Substances 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 102100022699 Lymphoid enhancer-binding factor 1 Human genes 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 244000062730 Melissa officinalis Species 0.000 description 1
• 235000010654 Melissa officinalis Nutrition 0.000 description 1
• 102100027240 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Human genes 0.000 description 1
• 244000246386 Mentha pulegium Species 0.000 description 1
• 235000016257 Mentha pulegium Nutrition 0.000 description 1
• 235000004357 Mentha x piperita Nutrition 0.000 description 1
• 108060004795 Methyltransferase Proteins 0.000 description 1
• 102000016397 Methyltransferase Human genes 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 102100030608 Mothers against decapentaplegic homolog 7 Human genes 0.000 description 1
• 102100034256 Mucin-1 Human genes 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 102000007474 Multiprotein Complexes Human genes 0.000 description 1
• 108010085220 Multiprotein Complexes Proteins 0.000 description 1
• 101100144701 Mus musculus Drosha gene Proteins 0.000 description 1
• 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
• 102100029447 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 Human genes 0.000 description 1
• 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
• 206010029113 Neovascularisation Diseases 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 108020003217 Nuclear RNA Proteins 0.000 description 1
• 102000043141 Nuclear RNA Human genes 0.000 description 1
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
• 239000012124 Opti-MEM Substances 0.000 description 1
• 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
• 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
• 102000016187 PAZ domains Human genes 0.000 description 1
• 108050004670 PAZ domains Proteins 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 239000007990 PIPES buffer Substances 0.000 description 1
• 102100026466 POU domain, class 2, transcription factor 3 Human genes 0.000 description 1
• 101710084413 POU domain, class 2, transcription factor 3 Proteins 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 102000003992 Peroxidases Human genes 0.000 description 1
• IAJOBQBIJHVGMQ-UHFFFAOYSA-N Phosphinothricin Natural products CP(O)(=O)CCC(N)C(O)=O IAJOBQBIJHVGMQ-UHFFFAOYSA-N 0.000 description 1
• ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 108010039918 Polylysine Proteins 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
• 208000037062 Polyps Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
• NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
• 102100022033 Presenilin-1 Human genes 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 102100032706 Protein Jade-1 Human genes 0.000 description 1
• 101710099377 Protein argonaute 2 Proteins 0.000 description 1
• 102100026774 Protein chibby homolog 1 Human genes 0.000 description 1
• 239000012083 RIPA buffer Substances 0.000 description 1
• 108091034057 RNA (poly(A)) Proteins 0.000 description 1
• 102000014450 RNA Polymerase III Human genes 0.000 description 1
• 108010078067 RNA Polymerase III Proteins 0.000 description 1
• 238000002123 RNA extraction Methods 0.000 description 1
• 238000010802 RNA extraction kit Methods 0.000 description 1
• 229940076189 RNA modulator Drugs 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 108091078663 RNase T family Proteins 0.000 description 1
• 238000010240 RT-PCR analysis Methods 0.000 description 1
• 241000269435 Rana <genus> Species 0.000 description 1
• 244000088415 Raphanus sativus Species 0.000 description 1
• 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
• 102100039663 Receptor-type tyrosine-protein phosphatase F Human genes 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 208000016624 Retinal neoplasm Diseases 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 108090000621 Ribonuclease P Proteins 0.000 description 1
• 102000004167 Ribonuclease P Human genes 0.000 description 1
• 108010046983 Ribonuclease T1 Proteins 0.000 description 1
• 101710141795 Ribonuclease inhibitor Proteins 0.000 description 1
• 229940122208 Ribonuclease inhibitor Drugs 0.000 description 1
• 102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
• 101700026522 SMAD7 Proteins 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 229920005654 Sephadex Polymers 0.000 description 1
• 239000012507 Sephadex™ Substances 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 108020004688 Small Nuclear RNA Proteins 0.000 description 1
• 102000039471 Small Nuclear RNA Human genes 0.000 description 1
• FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 108010048349 Steroidogenic Factor 1 Proteins 0.000 description 1
• 102100029856 Steroidogenic factor 1 Human genes 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 101710137500 T7 RNA polymerase Proteins 0.000 description 1
• 239000008051 TBE buffer Substances 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• 239000004098 Tetracycline Substances 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102100031027 Transcription activator BRG1 Human genes 0.000 description 1
• 108020004566 Transfer RNA Proteins 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
• 102100033015 Tyrosine-protein phosphatase non-receptor type 14 Human genes 0.000 description 1
• 108090000848 Ubiquitin Proteins 0.000 description 1
• 102000044159 Ubiquitin Human genes 0.000 description 1
• DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 208000002495 Uterine Neoplasms Diseases 0.000 description 1
• 102100039543 Uveal autoantigen with coiled-coil domains and ankyrin repeats Human genes 0.000 description 1
• XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
• 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• WCDYMMVGBZNUGB-ORPFKJIMSA-N [(2r,3r,4s,5r,6r)-6-[[(1r,3r,4r,5r,6r)-4,5-dihydroxy-2,7-dioxabicyclo[4.2.0]octan-3-yl]oxy]-3,4,5-trihydroxyoxan-2-yl]methyl 3-hydroxy-2-tetradecyloctadecanoate Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](COC(=O)C(CCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCC)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H]2OC[C@H]2O1 WCDYMMVGBZNUGB-ORPFKJIMSA-N 0.000 description 1
• HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 230000035508 accumulation Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 125000002015 acyclic group Chemical group 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 230000002730 additional effect Effects 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
• LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
• 210000001789 adipocyte Anatomy 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 239000011543 agarose gel Substances 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 108010080146 androgen receptors Proteins 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000003816 antisense DNA Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 238000000376 autoradiography Methods 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 230000003385 bacteriostatic effect Effects 0.000 description 1
• 235000009579 balsamo Nutrition 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 230000037429 base substitution Effects 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 208000026900 bile duct neoplasm Diseases 0.000 description 1
• 239000003833 bile salt Substances 0.000 description 1
• 229940093761 bile salts Drugs 0.000 description 1
• 238000002306 biochemical method Methods 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 229920001222 biopolymer Polymers 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 230000001914 calming effect Effects 0.000 description 1
• 230000000711 cancerogenic effect Effects 0.000 description 1
• 238000005251 capillar electrophoresis Methods 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 231100000315 carcinogenic Toxicity 0.000 description 1
• 210000004413 cardiac myocyte Anatomy 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 210000003855 cell nucleus Anatomy 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 210000004671 cell-free system Anatomy 0.000 description 1
• 108091092328 cellular RNA Proteins 0.000 description 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 239000002962 chemical mutagen Substances 0.000 description 1
• 229960005091 chloramphenicol Drugs 0.000 description 1
• WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 210000001612 chondrocyte Anatomy 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 238000002983 circular dichroism Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 230000000112 colonic effect Effects 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 201000010989 colorectal carcinoma Diseases 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 239000003184 complementary RNA Substances 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 230000030944 contact inhibition Effects 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 201000000159 corneal neovascularization Diseases 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 1
• IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 1
• 108091092330 cytoplasmic RNA Proteins 0.000 description 1
• 210000004292 cytoskeleton Anatomy 0.000 description 1
• SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
• SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
• RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
• HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
• NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
• 230000007423 decrease Effects 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000004340 degenerative myopia Effects 0.000 description 1
• 239000007857 degradation product Substances 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000002951 depilatory effect Effects 0.000 description 1
• 230000002074 deregulated effect Effects 0.000 description 1
• 230000036576 dermal application Effects 0.000 description 1
• 239000007933 dermal patch Substances 0.000 description 1
• 238000003795 desorption Methods 0.000 description 1
• 230000001687 destabilization Effects 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• ZPTBLXKRQACLCR-XVFCMESISA-N dihydrouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)CC1 ZPTBLXKRQACLCR-XVFCMESISA-N 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• VKFAUCPBMAGVRG-UHFFFAOYSA-N dipivefrin hydrochloride Chemical compound [Cl-].C[NH2+]CC(O)C1=CC=C(OC(=O)C(C)(C)C)C(OC(=O)C(C)(C)C)=C1 VKFAUCPBMAGVRG-UHFFFAOYSA-N 0.000 description 1
• 230000008034 disappearance Effects 0.000 description 1
• 231100000294 dose-dependent toxicity Toxicity 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 208000011325 dry age related macular degeneration Diseases 0.000 description 1
• 210000005069 ears Anatomy 0.000 description 1
• 230000005684 electric field Effects 0.000 description 1
• 238000009713 electroplating Methods 0.000 description 1
• 238000004520 electroporation Methods 0.000 description 1
• 238000000132 electrospray ionisation Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 210000002257 embryonic structure Anatomy 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 210000003372 endocrine gland Anatomy 0.000 description 1
• 210000004696 endometrium Anatomy 0.000 description 1
• 210000001163 endosome Anatomy 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
• 208000037828 epithelial carcinoma Diseases 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 210000003499 exocrine gland Anatomy 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 238000013265 extended release Methods 0.000 description 1
• 238000001125 extrusion Methods 0.000 description 1
• 206010016256 fatigue Diseases 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 201000008396 gallbladder adenocarcinoma Diseases 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 238000012224 gene deletion Methods 0.000 description 1
• 238000001476 gene delivery Methods 0.000 description 1
• 230000030279 gene silencing Effects 0.000 description 1
• 210000004602 germ cell Anatomy 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• IAJOBQBIJHVGMQ-BYPYZUCNSA-N glufosinate-P Chemical compound CP(O)(=O)CC[C@H](N)C(O)=O IAJOBQBIJHVGMQ-BYPYZUCNSA-N 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 229940074045 glyceryl distearate Drugs 0.000 description 1
• 229940075507 glyceryl monostearate Drugs 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
• 235000013928 guanylic acid Nutrition 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 208000006359 hepatoblastoma Diseases 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 235000001050 hortel pimenta Nutrition 0.000 description 1
• 102000051308 human DICER1 Human genes 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 230000000984 immunochemical effect Effects 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 208000015181 infectious disease Diseases 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 229960000318 kanamycin Drugs 0.000 description 1
• 229930027917 kanamycin Natural products 0.000 description 1
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
• 229930182823 kanamycin A Natural products 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 101150066555 lacZ gene Proteins 0.000 description 1
• 201000005264 laryngeal carcinoma Diseases 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
• 229960005287 lincomycin Drugs 0.000 description 1
• 239000000865 liniment Substances 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 206010024627 liposarcoma Diseases 0.000 description 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
• 238000009630 liquid culture Methods 0.000 description 1
• 239000007791 liquid phase Substances 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 201000002250 liver carcinoma Diseases 0.000 description 1
• 210000005229 liver cell Anatomy 0.000 description 1
• 230000031142 liver development Effects 0.000 description 1
• 208000022080 low-grade astrocytoma Diseases 0.000 description 1
• 201000005296 lung carcinoma Diseases 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 238000010801 machine learning Methods 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 230000007257 malfunction Effects 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 208000026037 malignant tumor of neck Diseases 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 230000013011 mating Effects 0.000 description 1
• 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 210000003593 megakaryocyte Anatomy 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
• 229940012189 methyl orange Drugs 0.000 description 1
• 229960001047 methyl salicylate Drugs 0.000 description 1
• 230000011987 methylation Effects 0.000 description 1
• YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
• 238000002493 microarray Methods 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 239000007758 minimum essential medium Substances 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• 229940051866 mouthwash Drugs 0.000 description 1
• 210000000107 myocyte Anatomy 0.000 description 1
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 239000006218 nasal suppository Substances 0.000 description 1
• 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 230000010309 neoplastic transformation Effects 0.000 description 1
• 201000003142 neovascular glaucoma Diseases 0.000 description 1
• 201000008026 nephroblastoma Diseases 0.000 description 1
• 208000007538 neurilemmoma Diseases 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 108010064131 neuronal Cdk5 activator (p25-p35) Proteins 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 102000042567 non-coding RNA Human genes 0.000 description 1
• 230000009871 nonspecific binding Effects 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 238000007899 nucleic acid hybridization Methods 0.000 description 1
• 229940127073 nucleoside analogue Drugs 0.000 description 1
• 231100000862 numbness Toxicity 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 108010092948 oligonucleotidase Proteins 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 210000000287 oocyte Anatomy 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 201000006958 oropharynx cancer Diseases 0.000 description 1
• 230000000399 orthopedic effect Effects 0.000 description 1
• 210000000963 osteoblast Anatomy 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 230000001151 other effect Effects 0.000 description 1
• QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
• 230000036407 pain Effects 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 238000012753 partial hepatectomy Methods 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 125000003933 pentacenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC5=CC=CC=C5C=C4C=C3C=C12)* 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• 150000008298 phosphoramidates Chemical class 0.000 description 1
• 150000008300 phosphoramidites Chemical class 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 208000010916 pituitary tumor Diseases 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 239000013600 plasmid vector Substances 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229920002401 polyacrylamide Polymers 0.000 description 1
• 208000030761 polycystic kidney disease Diseases 0.000 description 1
• 239000008389 polyethoxylated castor oil Substances 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 229920000656 polylysine Polymers 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 230000001124 posttranscriptional effect Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229960003975 potassium Drugs 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000004224 potassium gluconate Substances 0.000 description 1
• 229960003189 potassium gluconate Drugs 0.000 description 1
• 235000013926 potassium gluconate Nutrition 0.000 description 1
• 229910001414 potassium ion Inorganic materials 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 238000002731 protein assay Methods 0.000 description 1
• 230000004853 protein function Effects 0.000 description 1
• IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• 125000001725 pyrenyl group Chemical group 0.000 description 1
• YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 239000003340 retarding agent Substances 0.000 description 1
• 238000010839 reverse transcription Methods 0.000 description 1
• 239000003161 ribonuclease inhibitor Substances 0.000 description 1
• 108020004418 ribosomal RNA Proteins 0.000 description 1
• DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 230000009291 secondary effect Effects 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 235000012239 silicon dioxide Nutrition 0.000 description 1
• 235000020183 skimmed milk Nutrition 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 238000002791 soaking Methods 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 125000001935 tetracenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C12)* 0.000 description 1
• 229960002180 tetracycline Drugs 0.000 description 1
• 229930101283 tetracycline Natural products 0.000 description 1
• 235000019364 tetracycline Nutrition 0.000 description 1
• 150000003522 tetracyclines Chemical class 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000009752 translational inhibition Effects 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 230000005747 tumor angiogenesis Effects 0.000 description 1
• 239000000225 tumor suppressor protein Substances 0.000 description 1
• DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• 206010046766 uterine cancer Diseases 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 229940075420 xanthine Drugs 0.000 description 1
• 238000013316 zoning Methods 0.000 description 1